Clinical Trial Budget Example: A Line-Item Walkthrough

Every clinical trial site budget is built from the same three structural layers, regardless of therapeutic area, phase, or sponsor: one-time startup costs, recurring per-patient/per-visit costs, and an overhead (indirect cost) rate applied on top. The line items inside each layer are highly standardized across academic medical centers, contract research organizations (CROs), and sponsors — what varies is the dollar amount, not the structure. This guide walks through that structure using a single, clearly-labeled illustrative composite budget, so a research administrator, clinical trials office (CTO) analyst, or investigator building a first site budget can see how the pieces fit together before opening an actual budget template.

Why a worked example helps

Clinical trial budgeting is one of the more procedurally standardized parts of trial startup, but the standardization is rarely made visible in one place — most research administrators learn the structure from an institution-specific Excel template (academic medical centers including the University of Michigan Medical School, Johns Hopkins, the University of Virginia, and UCLA all publish their own internal versions) rather than from a single explanation of why the categories exist. Seeing one worked structure end to end makes it easier to sanity-check a real budget: does it separate startup from per-patient costs? Does it account for screen failures? Is overhead applied to the right base?

The three budget layers

1. Startup (one-time) costs

Costs incurred once, regardless of how many patients ultimately enroll:

• IRB/ethics review fee — initial protocol review, often billed separately from continuing review.
• Clinical Trial Agreement (CTA) negotiation — legal and budget-negotiation staff time; many institutions absorb this as overhead rather than a direct line item, but sponsors increasingly see it itemized, especially where a Model Clinical Trial Agreement (mCTA) is not used and negotiation runs longer than a templated agreement would.
• Site Initiation Visit (SIV) — sponsor/CRO monitor time plus site staff time to confirm the site is ready to enroll.
• EDC/CTMS build and training — study-specific configuration of the electronic data capture system and site staff training on it.
• Investigational product (IP)/pharmacy setup — pharmacy protocol review, storage qualification, dispensing-log setup.
• Regulatory document collection — building the site’s Trial Master File (TMF) essential-document set before first enrollment.
• Advertising/recruitment materials — where the site (rather than the sponsor centrally) develops and places recruitment materials.

2. Per-patient / per-visit costs

These recur for every enrolled patient and are usually the largest share of the budget by dollar volume. The structure is normally a grid: one row per visit (screening, baseline, each follow-up, end-of-study), one column per procedure (physical exam, labs, imaging, ECG, coordinator time, PI time), so the per-patient total is the sum of what each visit actually requires per protocol. Common line items:

• Screening visit — consent, eligibility procedures, screening labs.
• Screen failure fee — a separate, typically lower, flat fee paid for consented-but-not-eligible patients, since screening procedures were still performed and billed.
• Scheduled follow-up visits — itemized per protocol-required procedure at that visit.
• Unscheduled/safety visits — a per-visit rate for protocol-permitted but non-scheduled contacts (adverse event follow-up, dose interruption).
• Early termination/withdrawal visit — a distinct rate from a completed final visit, since procedures differ.
• Coordinator and investigator time — sometimes itemized per visit, sometimes rolled into a per-visit procedure rate.

3. Study-wide pass-through costs and overhead

• IRB continuing review — annual (or protocol-specified interval) re-review fees.
• Safety reporting — site effort to process and report serious adverse events (SAEs) to the IRB and sponsor.
• Data management/query resolution — ongoing coordinator time responding to EDC queries.
• Study closeout — final monitoring visit, TMF reconciliation, archival.
• Institutional overhead (indirect cost/F&A rate) — applied on top of some or all direct-cost categories above. For industry-sponsored clinical trials specifically, academic medical centers commonly apply a flat institutional rate against total direct costs rather than the federally negotiated research F&A rate used on grants — publicly posted examples fall roughly in the 25%-35% range (for example, institutions have publicly posted rates such as 35% of total direct costs, or 34% for off-campus commercial-sponsored clinical research), though the exact rate, the base it applies to, and which line items (IRB fees are sometimes excluded) it covers are all set independently by each institution and negotiated site by site — never assume one institution’s published rate for another.

How the pieces combine

At the structural level, a site’s total trial budget is approximately:

Total = Startup costs + (Per-patient cost × expected enrolled patients) + (Screen-failure fee × expected screen-failure count) + Study-wide pass-through costs, then overhead applied to the appropriate direct-cost base

The two numbers that most often get underestimated in a first draft are the expected screen-failure rate (which varies enormously by indication and eligibility criteria strictness) and unscheduled/safety visits — both are easy to omit from an early estimate and then become a real point of budget-negotiation friction with the sponsor once actual enrollment data starts coming in.

Budget construction vs. billing compliance — two different questions

Building the budget (this guide’s focus) answers “what does this trial cost to run, and how do we recover that cost from the sponsor?” A separate, related question is “which of these costs, if a study participant is also a Medicare beneficiary, may legally be billed to Medicare instead of the sponsor?” That second question is governed by CMS National Coverage Determination (NCD) 310.1, which distinguishes routine patient-care costs Medicare may cover for a beneficiary enrolled in a qualifying clinical trial from costs the sponsor must bear because they exist specifically to answer the research question. Getting this distinction wrong is the fact pattern behind real False Claims Act settlements over billing the same clinical trial cost to both the sponsor and Medicare. Budget construction and coverage analysis have to agree with each other line item by line item, but they are not the same exercise, and a well-built budget still needs a separate Medicare coverage analysis wherever a Medicare-eligible population is expected to enroll. For the full coverage-analysis process, see CASRAI’s Medicare Coverage Analysis for Clinical Trials guide.

Who builds and negotiates a clinical trial budget

At most academic medical centers, the initial internal budget is drafted by the site or the Clinical Trials Office (CTO), using the sponsor’s protocol and schedule of events, then negotiated back and forth against the sponsor’s or CRO’s proposed budget before both parties sign it as an exhibit to the Clinical Trial Agreement. Negotiation typically concentrates on per-patient procedure rates (whether they reflect current standard-of-care billing rates at that institution), the screen-failure fee, and the overhead rate/base — not the overall structure, which both sides already expect to follow the layers above.

Frequently asked questions

What are the three main categories in a clinical trial budget?

Startup (one-time) costs, per-patient/per-visit costs, and study-wide pass-through costs, with institutional overhead applied on top of some or all of the direct-cost categories. Nearly every institutional and sponsor budget template, however it labels the tabs, is organized around this same three-layer structure.

What is a screen failure fee and why is it separate from the per-patient rate?

A screen failure is a consented participant who does not ultimately meet eligibility criteria and is not enrolled. Screening procedures (consent, eligibility labs/exams) were still performed and cost the site money, so budgets pay a separate, typically lower, flat fee for each screen failure rather than folding that cost into the per-enrolled-patient rate.

How is the overhead/indirect cost rate applied to a clinical trial budget?

For industry-sponsored trials, most academic medical centers apply their own flat institutional rate (commonly in the roughly 25%-35% of total-direct-costs range, publicly posted rates vary by institution) rather than the federally negotiated F&A rate used on grant budgets, and the rate is applied on top of the direct-cost total described above — sometimes excluding specific line items such as IRB fees. Always confirm the current rate and its base with the institution’s own sponsored-programs or clinical trials office; it is set and updated independently by each institution.

Does a clinical trial budget need to match the Medicare coverage analysis?

Yes, line item by line item. The budget determines what the sponsor pays for; the coverage analysis (governed by CMS NCD 310.1) determines what, if anything, Medicare may pay for a Medicare-eligible participant’s routine care costs. The two documents need to agree on which costs sit where — billing the same cost to both the sponsor and Medicare is a real compliance and False Claims Act exposure, covered in CASRAI’s Medicare Coverage Analysis guide.

Who negotiates the clinical trial budget with the sponsor?

Typically the institution’s Clinical Trials Office or sponsored-programs office, in coordination with the principal investigator, negotiating against the sponsor’s or CRO’s proposed budget until both sides sign it as an exhibit to the Clinical Trial Agreement.